Recent development in chemotherapy of paediatric brain tumours

Current Opinion in Oncology

Volumn 19, Issue 6, 2007, Pages 612-615

  Grill, Jacques ^a   Bhangoo, Ranjeev ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Child; Clinical trial; Drug; Ependymoma; Glioma; Medulloblastoma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ERLOTINIB; ETOPOSIDE; GEFITINIB; IFOSFAMIDE; IMATINIB; LOMUSTINE; METHOTREXATE; OXALIPLATIN; PLATINUM; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; VINBLASTINE; VINCRISTINE;

BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SUBSTITUTION; GLIOMA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INFECTION; LEUKOENCEPHALOPATHY; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NEUROECTODERM TUMOR; NEUROTOXICITY; ONCOLOGY; OTOTOXICITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; MEDICAL ONCOLOGY; MEDULLOBLASTOMA; PEDIATRICS; TREATMENT OUTCOME;

EID: 34848839543     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f03152     Document Type: Review

References (36)

1. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352:978-986.
2. Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005; 6:573-580.
3. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 2005; 23:7621-7631.
4. Grill J, Lellouch-Tubiana A, Elouahdani S, et al. Preoperative chemotherapy in children with high-risk medulloblastomas: a feasibility study. J Neurosurg 2005; 103:312-318.
5. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24:4202-4208.
6. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23:8588-8596.
7. Verlooy J, Mosseri V, Bracard S, et al. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur J Cancer 2006; 42:3004-3014.
8. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7:813-820. This study used high-dose cyclophosphamide with stem-cell support given after craniospinal irradiation. It showed excellent results for high-risk as well as for standard-risk patients. For standard risk medulloblastoma, however, these results were not superior to other protocols with lower treatment burdens. In contrast, the 60% 5-year EFS in metastatic medulloblastomas represents the best results published so far in this poor prognosis population.
9. Ridola V, Grill J, Doz F, et al. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer 2007; 110:156-163.
10. Sung KW, Yoo KH, Cho EJ, et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 2007; 48:408-415.
11. Thorarinsdottir HK, Rood B, Kamani N, et al. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 2007; 48:278-284.
12. Gururangan S, Petros WP, Poussaint TY, et al. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res 2006; 12:1540-1546.
13. Benesch M, Sovinz P, Krammer B, et al. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol 2007; 29:222-226.
14. Baruchel S, Diezi M, Hargrave D, et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 2006; 42:2335-2342.
15. Fouladi M, Blaney SM, Poussaint TY, et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer 2006; 107:2291-2297.
16. von Bueren AO, Shalaby T, Rajtarova J, et al. Antiproliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC Cancer 2007; 7:19.
17. Damodar Reddy C, Guttapalli A, Adamson PC, et al. Anticancer effects of fenretinide in human medulloblastoma. Cancer Lett 2006; 231:262-269.
18. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A 2007; 104:8455-8460.
19. Lauth M, Bergstrom A, Toftgard R. Phorbol esters inhibit the Hedgehog signalling pathway downstream of Suppressor of Fused, but upstream of Gli. Oncogene 2007; 19 Feb [Epub ahead of print].
20. Sonnemann J, Kumar KS, Heesch S, et al. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 2006; 28:755-766.
21. Kumar KS, Sonnemann J, Hong le TT, et al. Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma. Anticancer Res 2007; 27:465-470.
22. Chamoun RB, Alaraj AM, Al Kutoubi AO, et al. Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. Acta Neurochir (Wien) 2006; 148:175-179.
23. Lee MJ, Ra YS, Park JB, et al. Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide, in the treatment of low-grade gliomas in children. J Neurooncol 2006; 80:277-284.
24. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59:490-498. Although the study concerned only a small number of patients with a very specific disease, it showed that with a sound biologic knowledge of a disease, one can devise very efficient therapeutics targeting the initiating abnormalities of the tumour. This is the first example of a hopefully long series of new agents in neuro-oncology.
25. Chintagumpala MM, Friedman HS, Stewart CF, et al. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the Children's Oncology Group. J Neurooncol 2006; 77:193-198.
26. MacDonald TJ, Arenson EB, Ater J, et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. Cancer 2005; 104:2862-2871.
27. Wolff JE, Wagner S, Reinert C, et al. Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol 2006; 79:315-321.
28. Broniscer A, Chintagumpala M, Fouladi M, et al. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol 2006; 76:313-319.
29. Donson AM, Addo-Yobo SO, Handler MH, et al. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 2007; 48:403-407.
30. Pollack IF, Hamilton RL, Sobol RW, et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 2006; 24:3431-3437.
31. Dufour C, Grill J, Lellouch-Tubiana A, et al. High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. Eur J Cancer 2006; 42:2939-2945.
32. Duffner PK, Krischer JP, Burger PC, et al. Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J Neurooncol 1996; 28:245-256.
33. Turner CD, Chi S, Marcus KJ, et al. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol 2007; 82:95-101.
34. Warren K, Jakacki R, Widemann B, et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol 2006; 58:343-347.
35. Hall WA, Doolittle ND, Daman M, et al. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol 2006; 77:279-284.
36. Freeman BB 3rd, Daw NC, Geyer JR, et al. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest 2006; 24:310-317.